ArticleCell communication and signaling : CCS2026
BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe body-protective polypeptide BPC157 is a natural therapeutic agent that has demonstrated robust efficacy in promoting repair across multiple organ systems, indicating its significant clinical potential. However, its clinical translation has been substantially hindered by a lack of understanding of its precise molecular mechanisms of action. Given its prominent proangiogenic effects, deciphering the mechanistic basis of its vascular regenerative actions is critically important.
methodsTo investigate the molecular pathway underlying the proangiogenic effects of BPC157, we employed a combination of molecular, biochemical, and cellular approaches. These include techniques to identify protein‒protein interactions, assess ubiquitination status, and evaluate key cellular functions. The specific role of the proline residue at position 3 of BPC157 was also experimentally validated.
resultsWe revealed that intracellular BPC157 engages the E3 ubiquitin ligase adaptor protein FBXO22 through its proline residue at position 3. This interaction results in the formation of a protein complex that effectively suppresses the ubiquitination and subsequent proteasomal degradation of the transcription factor BACH1, leading to significant stabilization of BACH1 protein levels. The consequent accumulation of BACH1 was shown to enhance critical processes in vascular regeneration, namely, the proliferation and tube-forming capacity of vascular endothelial cells.
conclusionsThis study establishes a novel and critical molecular mechanism for the pharmacological actions of BPC157, centered on the BPC157-FBXO22-BACH1 axis. These findings provide a solid mechanistic foundation for the future development of BPC157-based or sequential therapeutic agents targeted at enhancing vascular repair. Furthermore, this work offers robust scientific evidence that can inform improved strategies for the prevention and treatment of tissue injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.